Without any underwriters, lawyers, auditors, or financials…
Well, this is a new one. Have you ever watched a TV show like Grey’s Anatomy and thought, “Yeah, I could do surgery.” The answer is no, no you can’t.
SPACs, which to many people might seem simple on the surface, are actually quite complex. In fact, even very experienced lawyers, if they don’t have SPAC experience, sometimes quickly find themselves struggling to navigate SPAC regulatory waters.
However, GRD Biotechnology (NASDAQ: CGRD), submitted its S-1 filing for a $40 million IPO this afternoon, but without any expertise attached. That means this was filed without the counsel of underwriters, lawyers or auditors advising them on the process. This is not a good idea.
Additionally, it reads as if someone asked ChatGPT to write a SPAC S-1. To wit, the bio of Zhonghua Gao, who serves as Chairman and Chief Executive Officer, has a sentence that reads as, “He has a certain influence in related industries.”
I guess he has good “vibes”?
It’s hard to say if this filing was published by accident or if it’s real, but the terms seem to imply the former. Or perhaps it’s an elaborate hoax. That’s because the terms included in this filing befit an experienced serial SPAC issuer with 24 months to find a combination, 100% held in trust (or $10.00 day-one), and no warrants or rights included in the IPO unit. These terms would be hard to come by for even top notch teams in 2021. Certainly not in 2023.
But, on the off chance this team actually meant to file this, GRD Biotechnology is a $40 million offering and intends to focus on the Asian biotechnology sector. GRD believes this market opportunity is vast and highly diverse, but intends to have a particular focus on medical devices, especially in the region of China.
The SPAC is led by Chairman and CEO Zhonghua Gao, and his bio in the filing states he brings more than 20 years of experience in biotechnology, human cell and gene biological testing, and general health. Mr. Gao has served as Dean of the Gene Technology Research Institute, Chairman of Zhongjianlian Biotechnology Co., Ltd., and Chairman of Sichuan Gaorunde Biotechnology Co., Ltd.
Mr. Gao is joined by CFO Meimei Xiao, who has over two decades of experience in the finance sector, but the filing does not elaborate on the roles or at what companies. However, Ms. Xiao is currently the financial director of a company listed on the Shanghai stock exchange (un-named) and is currently the financial director of Sichuan Gaorunde Biotechnology Co., Ltd.
We’ve added GRD Biotechnology to the database as a SPAC on file to IPO, but this deal will be hard pressed to make it through SEC review in its current form. Nonetheless, it will be interesting to see if there is a subsequent amendment filed.
SPAC TERMS
Terms Tracker for the Week Ending May 9, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. After the sprint that was last week, with nine IPOs and six new SPAC filings, this week took a breather. Only two SPACs priced, there...
Lake Superior (NASDAQ:LKSPU) has filed for a $100 million SPAC as its CEO attempts to go three-for-three with SPACs that led to completed deals. This new vehicle has one right to a 1/6 share in each unit and some common features of a SPAC underwritten by Cohen & Company in this current climate. Although the...
At the SPAC of Dawn De-SPACs were among the biggest movers in yesterday’s stock market rally, but most of this momentum came on the backs of direct earnings performance. Only three US-listed companies had bigger one-day gains than quantum computing firm D-Wave’s (NYSE:QBTS) +51.2% jump. This came as the company announced $15 million in revenue...
EGH Acquisition Corp. (NASDAQ:EGHAU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “EGHAU”, Friday, May 8, 2025. The new SPAC aims to combine with a target company in the energy transition or sustainability arena that help industries achieve efficiencies and decarbonization....
At the SPAC of Dawn Fed Chair Jerome Powell announced yesterday that the body intends to keep rates unchanged, earning him the moniker “FOOL” by US President Donald Trump. But, the announcement could bring some stability to market, which has seen macro factors pull it a variety of directions since the start of the year....